ElleVet Sciences announced publication of a feline mobility study in The Journal of Feline Medicine and Surgery which it said demonstrates the safety and efficacy of the company's CBD + CBDA formulation for cats experiencing mobility challenges.
The randomized, double-blinded, placebo-controlled crossover study evaluated a six-week course of cannabidiol (CBD)/cannabidiolic acid (CBDA)-rich hemp paste in cats experiencing mobility challenges. Each cat received both the paste and placebo in sequence.
In cats who completed the study, the CBD/CBDA paste produced statistically significant results reported by both veterinarians and owners. Specific measures of mobility, including gait, navigating stairs, jumping up and down, and play behavior improved during the study in cats who received CBD/CBDA. Bloodwork showed no significant safety concerns between groups after six weeks of use.
"An overwhelming number of cats experience mobility challenges, but there are very limited safe and effective long-term options to help," said Joseph Wakshlag, DVM, PhD, DACVIM (Nutrition), DACVSMR and chief veterinary medical officer of ElleVet. "Our goal with this research, and its application in ElleVet's feline products, is to fill a significant void in feline care; the improvement reported from vets and cat owners in this study validates our efforts."
Haley Israelson, CEO of ElleVet Sciences, said the company's science-first approach to understand and address the unique needs of cats has long been a driving force behind ElleVet. "We're thrilled to publish this research and highlight our impact in expanding mobility support options for cats," said Israelson. "This ultimately, improves quality of life – both for cats and the people who love them."
